US generic inhalation solutions manufacturer Nephron Pharmaceuticals has licensed Apotex’s generic budesonide inhalation suspension, a generic version of AstraZeneca’s Pulmicort Respules, and subsequently launched the product in the US, the company said. Nephron will manufacture, market, and distribute 0.5mg/2mL and 0.25mg/2mL dosage forms.
The company’s other products include albuterol, racepinephrine, ipratropium, and albuterol/ipratropium inhalation solutions.
Nephron Owner and CEO Lou Kennedy commented, “Nephron is delighted to enhance our generic respiratory portfolio with the launch of budesonide inhalation suspension. This new product approval is another milestone signaling growth for the company, which further complements our recent expansion into a fully automated state of the art manufacturing facility in West Columbia, South Carolina.”
Read the Nephron press release.
